Physician profile
Robert Guevara
NPI 1447310776
$4,109.21
in general payments reported to CMS, 2019-2025
17 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $171 · 2021: $46.91 · 2022: $494 · 2023: $754 · 2024: $1,054 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,715.80 |
| Education | $222.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,389.00 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $687.06 | 2021-2025 | Caplyta |
| Alkermes, INC. | $515.16 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $371.26 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $368.85 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $254.99 | 2019-2024 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $137.67 | 2024-2025 | Fanapt |
| Coopersurgical, INC. | $100.00 | 2020 | |
| Ironshore Pharmaceuticals INC. | $52.23 | 2019-2022 | |
| Lundbeck LLC | $45.66 | 2019-2020 | |
| Abbvie INC. | $36.92 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $35.24 | 2019 | |
| Corium, LLC | $34.82 | 2023 | Azstarys |
| Indivior INC. | $30.29 | 2023-2024 | Sublocade |
| Axsome Therapeutics, INC. | $18.73 | 2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $17.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.88 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.